Unknown PHASE4 INTERVENTIONAL 2-arm NCT04135677

Clinical Outcomes Between Anticoagulation and DAPT Therapy in AF Patients Successfully Undergoing LAAO

A Multi-center Randomized Controlled Study of High/Low-dosage Rivaroxaban Compared With DAPT After Left Atrial Appendage Occulsion in Patients With Non-valvular Atrial Fibrillation（ESCORT-AF Study(B)）

Sponsor: Shanghai Zhongshan Hospital

Conditions Left Atrial Appendage Thrombosis Stroke Thrombi

Interventions DAPT Rivaroxaban

Updated 7 times since 2019 Last updated: Nov 10, 2022 Started: Nov 11, 2022 Primary completion: Oct 1, 2024 Completion: Oct 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Left Atrial Appendage Thrombosis and Stroke and is currently ongoing. Shanghai Zhongshan Hospital leads this study, which shows 7 recorded versions since 2022 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

7 versions recorded

Dec 2024 — Present [monthly]

Unknown PHASE4

Status: Recruiting → Unknown
Sep 2024 — Dec 2024 [monthly]

Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE4
Dec 2022 — Jul 2024 [monthly]

Recruiting PHASE4

Status: Unknown Status → Recruiting
Nov 2021 — Dec 2022 [monthly]

Unknown Status PHASE4

Status: Not Yet Recruiting → Unknown Status

▶ Show 2 earlier versions

Jan 2021 — Nov 2021 [monthly]

Not Yet Recruiting PHASE4
Nov 2019 — Jan 2021 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Zhongshan Hospital

Data source: Shanghai Zhongshan Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China